Krystal Biotech falls on Q1 results miss

Krystal Biotech

06/05/2025 14:26

** Shares of drugmaker Krystal Biotech KRYS.O fall 9.8% to $146.4

** KRYS posts Q1 revenue of $88.2 million, missing analysts' average estimate of $96.24 million, according to data compiled by LSEG

** Co reports Q1 adj. profit of $1.20/share vs analysts' estimate of $1.37/share

** Krystal Biotech has one approved drug on the market, Vyjuvek, a gene therapy used to treat dystrophic epidermolysis bullosa (DEB), a rare genetic skin condition

    ** Patients with the condition suffer from open wounds, causing skin infections, and are at an increased risk of vision loss, scarring and skin cancer

** As of last close, KRYS stock up 3.6% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))